GO:1901492 positive regulation of lymphangiogenesis: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901492 (positive regulation of lymphangiogenesis) describes any process that activates or increases the frequency, rate or extent of lymphangiogenesis, the formation of new lymphatic vessels.
• Pro-lymphangiogenic signals are dominated by VEGF-C/VEGFR-3 and VEGF-D/VEGFR-3 axes, which are modulated by cytokines, extracellular matrix cues, and metabolic reprogramming.
• Positive regulation of lymphangiogenesis is essential for bone regeneration after injury, where lymphatic vessels support hematopoietic and osteogenic recovery.
• Tumor-associated lymphangiogenesis promotes lymph node metastasis in cervical, gastric, and other cancers, and is driven by factors such as FABP5, LCN2, and integrin α6-containing extracellular vesicles.
• Negative regulators such as Tenascin-C can delay inflammation resolution by suppressing lymphangiogenesis, highlighting the importance of balanced regulation.
• MicroRNAs provide an additional layer of post-transcriptional control over developmental lymphangiogenesis.
Description
Lymphangiogenesis is the process by which new lymphatic vessels form from pre-existing lymphatic endothelial cells. It is critical for tissue fluid homeostasis, immune cell trafficking, and lipid absorption. The Gene Ontology term GO:1901492, positive regulation of lymphangiogenesis, captures any molecular event that activates or increases the frequency, rate, or extent of this process. This term is distinct from lymphangiogenesis itself (GO:0001946) and from negative regulation of lymphangiogenesis, and it is used to annotate gene products that promote lymphatic vessel formation. Researchers study positive regulation of lymphangiogenesis because it plays dual roles in health and disease: it supports tissue repair and regeneration, but it also contributes to tumor metastasis and chronic inflammation. Understanding the positive regulators of lymphangiogenesis is therefore essential for developing therapies that either enhance lymphatic repair or block pathological lymphangiogenesis. This article synthesizes current knowledge from QuickGO and peer-reviewed literature to provide a research-grade overview of GO:1901492, including its mechanisms, key genes, disease relevance, and experimental models.
positive regulation of lymphangiogenesis At A Glance
| GO ID | GO:1901492 |
|---|---|
| GO term | positive regulation of lymphangiogenesis |
| Ontology | biological_process |
| Synonym | activation of lymphangiogenesis; upregulation of lymphangiogenesis; positive regulation of lymph vessel formation |
| Major function | Promotes the formation of new lymphatic vessels by activating signaling pathways, transcription factors, and cellular behaviors in lymphatic endothelial cells |
| Parent term | regulation of lymphangiogenesis (GO:1901491) |
| Related term | lymphangiogenesis (GO:0001946) |
| Process type | Positive regulation; biological process |
| Taxonomic range | Eukaryota |
What Is GO:1901492?
GO:1901492, positive regulation of lymphangiogenesis, is defined by QuickGO as any process that activates or increases the frequency, rate or extent of lymphangiogenesis. In other words, it encompasses all molecular signals, pathways, and cellular events that promote the formation of new lymphatic vessels from existing ones. This term is a biological process and is a child of positive regulation of developmental process and regulation of lymphangiogenesis. Synonyms include activation of lymphangiogenesis, upregulation of lymphangiogenesis, and positive regulation of lymph vessel formation.
Why Is positive regulation of lymphangiogenesis Important in Cell Biology?
Positive regulation of lymphangiogenesis is critically important because lymphatic vessels are indispensable for tissue fluid balance, immune surveillance, and lipid transport. In pathological settings, excessive lymphangiogenesis contributes to tumor metastasis, lymphedema, and inflammatory diseases, while insufficient lymphangiogenesis impairs wound healing and tissue regeneration. Therefore, understanding the positive regulators of lymphangiogenesis offers therapeutic opportunities to either promote lymphatic repair or inhibit pathological lymphangiogenesis.
• Promotes tissue regeneration: lymphatic vessels support bone regeneration after injury, and positive regulation of lymphangiogenesis is required for this process.
• Drives tumor metastasis: lymphangiogenesis in tumors facilitates lymph node metastasis in cervical, gastric, and other cancers.
• Modulates inflammation: negative regulators such as Tenascin-C delay inflammation resolution by suppressing lymphangiogenesis, indicating that positive regulators promote resolution.
• Influences developmental processes: microRNAs control developmental lymphangiogenesis, and their dysregulation can affect lymphatic development.
• Involved in metabolic reprogramming: FABP5-mediated fatty acid metabolism promotes lymph node metastasis and lymphangiogenesis in cervical cancer.
• Mediated by extracellular vesicles: integrin α6-containing extracellular vesicles promote lymphatic remodeling for pre-metastatic niche formation.
• Regulated by cytokines: various cytokines, including VEGF-C and VEGF-D, positively regulate lymphangiogenesis.
• Target for traditional medicine: Taohong Siwu Decoction, a traditional Chinese medicine, is used as adjuvant treatment for breast cancer and may affect lymphangiogenesis.
• Potential therapeutic target for lymphedema and wound healing.
• Key area for understanding immune cell trafficking and lipid absorption.
What Happens During positive regulation of lymphangiogenesis?
Initiation by Pro-Lymphangiogenic Factors
In simple terms: Signals from outside the cell tell lymphatic endothelial cells to start forming new vessels.
Positive regulation of lymphangiogenesis begins with the binding of pro-lymphangiogenic growth factors, such as VEGF-C and VEGF-D, to their receptors on lymphatic endothelial cells. Cytokines play a central role in this process, as reviewed by Sáinz-Jaspeado et al.. These signals activate intracellular pathways that drive cell proliferation, migration, and tube formation. In bone regeneration, lymphatic vessels are essential for recovery after injury, and their formation is positively regulated by factors released in the injury microenvironment.
Activation of Signaling Cascades
In simple terms: Inside the cell, a relay of molecular switches turns on genes that build new vessels.
Upon receptor activation, downstream signaling cascades including PI3K/AKT, MAPK/ERK, and Rho GTPase pathways are engaged. These pathways promote lymphatic endothelial cell survival, proliferation, and migration. FABP5, a fatty acid-binding protein, promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism, which in turn supports lymphangiogenesis. Similarly, LCN2-dependent positive-feedback loops between gastric cancer cells and tumor-associated macrophages mediate lymphangiogenesis and lymphatic metastasis.
Extracellular Matrix Remodeling and Vesicle-Mediated Communication
In simple terms: The environment around cells is reshaped, and tiny packages called vesicles carry signals to promote vessel growth.
Extracellular matrix components and extracellular vesicles modulate lymphangiogenesis. Integrin α6-containing extracellular vesicles promote lymphatic remodeling for pre-metastatic niche formation in lymph nodes via interplay with CD151. Tenascin-C, an extracellular matrix protein, negatively regulates lymphangiogenesis and delays inflammation resolution, indicating that its absence or inhibition can enhance lymphangiogenesis.
MicroRNA-Mediated Post-Transcriptional Control
In simple terms: Small RNA molecules fine-tune the production of proteins that control vessel growth.
MicroRNAs provide an additional layer of regulation. Jung et al. demonstrated that microRNA-mediated control is essential for developmental lymphangiogenesis, and dysregulation of these microRNAs can alter the positive regulation of lymphangiogenesis. This post-transcriptional control ensures precise spatial and temporal expression of pro-lymphangiogenic factors.
Integration with Tissue-Specific Regeneration
In simple terms: New lymphatic vessels help tissues like bone heal after injury.
In bone, lymphatic vessels support regeneration after injury. Biswas et al. showed that lymphatic vessels in bone are required for regeneration, and positive regulation of lymphangiogenesis is part of the healing response. This highlights the importance of context-specific regulation in tissue repair.
Key Genes Involved in GO:1901492 positive regulation of lymphangiogenesis
The following genes and proteins are key players in the positive regulation of lymphangiogenesis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFC | Primary pro-lymphangiogenic growth factor | Central regulator; target for promoting or inhibiting lymphangiogenesis |
| VEGFD | Pro-lymphangiogenic growth factor | Similar to VEGFC; involved in lymphatic metastasis |
| FLT4 (VEGFR-3) | Receptor for VEGFC/VEGFD | Mediates pro-lymphangiogenic signaling |
| FABP5 | Fatty acid-binding protein; promotes lymphangiogenesis via metabolic reprogramming | Promotes lymph node metastasis in cervical cancer |
| LCN2 | Lipocalin-2; mediates feedback loop with macrophages | Drives lymphangiogenesis and lymphatic metastasis in gastric cancer |
| ITGA6 | Integrin α6; component of extracellular vesicles | Promotes lymphatic remodeling and pre-metastatic niche formation |
| CD151 | Tetraspanin; interacts with integrin α6 | Facilitates extracellular vesicle-mediated lymphangiogenesis |
| TNC | Tenascin-C; negative regulator of lymphangiogenesis | Delays inflammation resolution; potential target to enhance lymphangiogenesis |
| MIRNAs | MicroRNAs; post-transcriptional regulators | Control developmental lymphangiogenesis |
| PROX1 | Transcription factor; master regulator of lymphatic endothelial cell identity | Essential for lymphangiogenesis; not directly cited in provided references but widely known |
| PDPN (Podoplanin) | Lymphatic endothelial cell marker | Used to identify lymphatic vessels in studies |
| LYVE1 | Lymphatic vessel endothelial hyaluronan receptor 1 | Marker for lymphatic endothelial cells |
| CCL21 | Chemokine; guides immune cell trafficking | Expressed by lymphatic endothelial cells; involved in immune function |
| CXCL12 | Chemokine; involved in lymphangiogenesis | May promote lymphatic metastasis |
| IL6 | Cytokine; can promote lymphangiogenesis | Inflammatory mediator |
| TNF | Cytokine; modulates lymphangiogenesis | Inflammatory mediator |
| TGFB1 | Cytokine; context-dependent regulator | Can promote or inhibit lymphangiogenesis |
| HGF | Growth factor; promotes lymphangiogenesis | Cytokine regulating lymphangiogenesis |
How Is positive regulation of lymphangiogenesis Regulated?
Positive regulation of lymphangiogenesis is controlled at multiple levels. Cytokines such as VEGF-C, VEGF-D, HGF, and inflammatory cytokines directly stimulate lymphatic endothelial cells. Metabolic pathways, including fatty acid metabolism via FABP5, can reprogram cells to support lymphangiogenesis. Extracellular matrix components like Tenascin-C negatively regulate the process, and their downregulation enhances lymphangiogenesis. MicroRNAs fine-tune the expression of pro-lymphangiogenic factors post-transcriptionally. Additionally, tumor-associated macrophages and cancer cells can form positive-feedback loops involving LCN2 to sustain lymphangiogenesis. This complex regulation ensures that lymphangiogenesis occurs in a context-appropriate manner.
positive regulation of lymphangiogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FABP5 | Cervical cancer lymph node metastasis | Knockout or overexpression in cervical cancer cell lines; mouse metastasis model |
| LCN2 | Gastric cancer lymphangiogenesis and metastasis | Knockout mice or gastric cancer xenografts |
| ITGA6/CD151 | Pre-metastatic niche formation in lymph nodes | Extracellular vesicle isolation and functional assays; knockout models |
| TNC | Inflammation resolution | Knockout mice for Tenascin-C; inflammation models |
| VEGFC/VEGFD | Lymphangiogenesis in development and disease | Transgenic overexpression or conditional knockout mice |
Cancer Metastasis
Positive regulation of lymphangiogenesis is a key driver of lymph node metastasis in many cancers. In cervical cancer, FABP5 promotes lymph node metastasis by reprogramming fatty acid metabolism, which enhances lymphangiogenesis. In gastric cancer, an LCN2-dependent positive-feedback loop between cancer cells and tumor-associated macrophages mediates lymphangiogenesis and lymphatic metastasis. Integrin α6-containing extracellular vesicles promote lymphatic remodeling for pre-metastatic niche formation in lymph nodes. These findings highlight lymphangiogenesis as a therapeutic target for blocking metastasis.
Inflammation and Its Resolution
Lymphangiogenesis is intimately linked to inflammation. Tenascin-C negatively regulates lymphangiogenesis and delays the resolution of inflammation, suggesting that positive regulators of lymphangiogenesis promote inflammation resolution. Cytokines that regulate lymphangiogenesis also modulate inflammatory responses. Thus, enhancing lymphangiogenesis may be beneficial in chronic inflammatory conditions.
Tissue Regeneration and Repair
Lymphatic vessels support regeneration after injury. In bone, lymphatic vessels are required for regeneration, and positive regulation of lymphangiogenesis is part of the healing process. This suggests that promoting lymphangiogenesis could enhance tissue repair in bone and possibly other tissues.
Lymphedema and Lymphatic Insufficiency
Although not directly cited in the provided references, insufficient lymphangiogenesis can lead to lymphedema. Understanding positive regulators may offer therapeutic strategies for lymphedema by promoting lymphatic vessel growth. The cytokines and pathways described are potential targets.
From positive regulation of lymphangiogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X promote lymphangiogenesis in vivo? | Knockout mouse model with lymphatic vessel quantification |
| Does a point mutation in gene Y affect its pro-lymphangiogenic activity? | Point mutation knock-in mice or cells |
| Does overexpression of gene Z enhance lymphangiogenesis? | Transgenic overexpression or viral delivery |
| Does a tagged version of protein W localize to lymphatic endothelial cells? | Tagged knock-in (e.g., GFP) |
| Does gene V regulate developmental lymphangiogenesis? | Zebrafish or mouse developmental models |
| Does gene U mediate tumor-associated lymphangiogenesis? | Orthotopic tumor models with lymphatic metastasis readout |
How to Study the positive regulation of lymphangiogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immunofluorescence for LYVE1/PDPN | Lymphatic vessel density | Tissue sections from mouse models |
| Tube formation assay | In vitro lymphangiogenesis | LEC culture with pro- or anti-lymphangiogenic factors |
| Extracellular vesicle tracking | Vesicle-mediated signaling | Pre-metastatic niche studies |
| MicroRNA sequencing | MicroRNA expression changes | Developmental lymphangiogenesis |
| Lymph node metastasis assay | Metastatic burden | Cancer models |
| Fatty acid metabolism assays | Metabolic reprogramming | Cancer lymphangiogenesis |
| Macrophage co-culture | Cell-cell interaction | LCN2 feedback loop |
| Inflammation resolution models | Resolution kinetics | Tenascin-C studies |
In Vivo Lymphangiogenesis Assays
Mouse models of corneal lymphangiogenesis, tail lymphedema, and tumor lymphangiogenesis are standard for studying positive regulation of lymphangiogenesis. These assays allow quantification of lymphatic vessel density and function.
Lymphatic Endothelial Cell Culture and Functional Assays
Primary lymphatic endothelial cells (LECs) can be used for proliferation, migration, and tube formation assays. These in vitro models help dissect molecular mechanisms of pro-lymphangiogenic factors.
Extracellular Vesicle Analysis
Extracellular vesicles can be isolated from conditioned media and characterized for their ability to promote lymphangiogenesis. Integrin α6-containing vesicles are an example.
MicroRNA Profiling and Functional Studies
MicroRNA mimics and inhibitors can be used to study post-transcriptional regulation of lymphangiogenesis. Developmental models are particularly useful.
How CRISPR Can Be Used to Study GO:1901492 positive regulation of lymphangiogenesis
Knockout
CRISPR knockout of pro-lymphangiogenic genes such as VEGFC, FABP5, or LCN2 can abolish lymphangiogenesis in cell and animal models. This helps establish causality. For example, knockout of FABP5 in cervical cancer cells would test its role in lymph node metastasis.
Point Mutation
Point mutations can be introduced to study specific residues in receptors like VEGFR-3 or in signaling molecules. This allows dissection of phosphorylation sites or binding interfaces critical for positive regulation of lymphangiogenesis.
Knock-in
Knock-in of reporter genes (e.g., GFP) or tags into endogenous loci such as LYVE1 or PDPN enables visualization and tracking of lymphatic endothelial cells in vivo.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression can be used to elevate pro-lymphangiogenic factors like VEGF-C to enhance lymphangiogenesis in models of tissue repair or lymphedema.
How EDITGENE Supports positive regulation of lymphangiogenesis Research
Researchers studying positive regulation of lymphangiogenesis-related genes often need to determine whether a candidate gene is causally involved in promoting lymphatic vessel formation. EDITGENE provides comprehensive CRISPR-based services to enable such investigations.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of lymphangiogenesis research.
Frequently Asked Questions About positive regulation of lymphangiogenesis
What is GO:1901492?
GO:1901492 is the Gene Ontology term for positive regulation of lymphangiogenesis, defined as any process that activates or increases the frequency, rate or extent of lymphangiogenesis.
What genes are involved in positive regulation of lymphangiogenesis?
Key genes include VEGFC, VEGFD, FLT4 (VEGFR-3), FABP5, LCN2, ITGA6, CD151, and TNC, among others.
How is positive regulation of lymphangiogenesis studied?
It is studied using in vivo mouse models, lymphatic endothelial cell culture, extracellular vesicle analysis, and microRNA profiling.
What diseases are associated with positive regulation of lymphangiogenesis?
It is associated with cancer metastasis, inflammation resolution, tissue regeneration, and potentially lymphedema.
What is the role of FABP5 in lymphangiogenesis?
FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism, which supports lymphangiogenesis.
How does LCN2 mediate lymphangiogenesis?
LCN2 mediates a positive-feedback loop between gastric cancer cells and tumor-associated macrophages, promoting lymphangiogenesis and lymphatic metastasis.
What is the role of Tenascin-C in lymphangiogenesis?
Tenascin-C negatively regulates lymphangiogenesis and delays the resolution of inflammation.
How do microRNAs control lymphangiogenesis?
MicroRNAs provide post-transcriptional control of developmental lymphangiogenesis by targeting pro-lymphangiogenic factors.
Can CRISPR be used to study positive regulation of lymphangiogenesis?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect gene function in lymphangiogenesis.
What are the therapeutic implications of targeting positive regulation of lymphangiogenesis?
Therapeutic targeting could block tumor metastasis or enhance tissue repair and inflammation resolution.
Conclusion
GO:1901492, positive regulation of lymphangiogenesis, is a critical biological process with profound implications for development, tissue repair, and disease. The interplay of growth factors, cytokines, metabolic pathways, extracellular vesicles, and microRNAs ensures precise control of lymphatic vessel formation. Dysregulation contributes to cancer metastasis and chronic inflammation, making this process an attractive therapeutic target. Continued research using advanced CRISPR models and multi-omics approaches will further unravel the complexities of lymphangiogenesis and pave the way for novel interventions.
References
- 1. Biswas L et al.. 2023. Lymphatic vessels in bone support regeneration after injury.. Cell 186(2):382-397.e24 PMID: 36669473
- 2. Katoh D et al.. 2025. Negative regulation of lymphangiogenesis by Tenascin-C delays the resolution of inflammation.. iScience 28(2):111756 PMID: 39925433
- 4. Sáinz-Jaspeado M et al.. 2018. Cytokines regulating lymphangiogenesis.. Curr Opin Immunol 53:58-63 PMID: 29680577
- 5. Zhang C et al.. 2020. FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism.. Theranostics 10(15):6561-6580 PMID: 32550890
- 6. Lin Y et al.. 2024. Integrin α6-containing extracellular vesicles promote lymphatic remodelling for pre-metastatic niche formation in lymph nodes via interplay with CD151.. J Extracell Vesicles 13(10):e12518 PMID: 39329462
- 7. Jung HM et al.. 2019. MicroRNA-mediated control of developmental lymphangiogenesis.. Elife 8 PMID: 31478836
- 8. Huang Z et al.. 2025. An LCN2-Dependent Positive-Feedback Loop Between Gastric Cancer Cells and Tumor-Associated-Macrophages Mediates Lymphangiogenesis and Lymphatic Metastasis.. Adv Sci (Weinh) 12(44):e08352 PMID: 40884261
